financetom
Business
financetom
/
Business
/
AmEx profit jumps on strong holiday season spending
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AmEx profit jumps on strong holiday season spending
Jan 24, 2025 4:26 AM

(Reuters) - American Express ( AXP ) reported a 12% jump in fourth-quarter profit on Friday, as more consumers swiped cards during the holiday season for travel and online shopping.

A strong holiday season against the backdrop of a falling rate environment helped AmEx sustain spending volumes.

AmEx, which mostly caters to wealthy consumers, has been able to better navigate economic uncertainty compared to some of its peers, as higher-earning individuals are less sensitive to inflation and elevated borrowing costs.

Shares of the company dipped 0.3% before the bell.

Billed business, a measure of spending on AmEx cards, rose 8% to $408.4 billion from last year in the fourth quarter.

The company's profit rose to $2.17 billion, or $3.04 per share, in the three months ended Dec. 31, from $1.93 billion, or $2.62 per share, a year earlier.

"We exited the year with increased momentum, with billings growth accelerating to 8 percent in the fourth quarter, driven by stronger spending from our consumer and commercial customers during the holiday season," CEO Stephen Squeri said.

New York-based AmEx's revenue rose 9% to $17.18 billion.

Meanwhile, AmEx's provisions for credit losses, fell to $1.3 billion in the quarter, compared with $1.4 billion a year earlier.

A resilient economy and a string of rate cuts by the Federal Reserve have eased concerns around credit quality. AmEx's affluent consumers have also allowed the company to scale back loan loss provisions compared with peers that serve a broad spectrum of customers.

AmEx expects 2025 earnings per share to be between $15 and $15.50, compared with analysts' estimates of $15.23, according to estimates compiled by LSEG.

The company also forecast 2025 revenue growth between 8% and 10%, compared with Street expectations of 8.1%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BP Azerbaijan says working to resume work of Shah Deniz platform as soon as possible
BP Azerbaijan says working to resume work of Shah Deniz platform as soon as possible
Jan 13, 2025
BAKU, Jan 13 (Reuters) - BP is working to resolve technical problems at the Shah Deniz Alfa (SDA) platform and hopes to resume normal operations as soon as possible, the company told Reuters on Monday. BP suspended work of the platform on Friday after detecting a technical issue at the subsea gas condensate export line between the platform and the...
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Jan 13, 2025
04:47 AM EST, 01/13/2025 (MT Newswires) -- Caribou Biosciences ( CRBU ) said Sunday it initiated the phase 1 trial evaluating its experimental therapy, CB-010, in patients with lupus nephritis and extrarenal lupus. Additionally, the company said it expects to report data from a study of CB-010 to treat certain large B cell lymphoma patients in the first half of...
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Jan 13, 2025
04:32 AM EST, 01/13/2025 (MT Newswires) -- Teva Pharmaceutical Industries' ( TEVA ) Teva Pharmaceuticals International subsidiary said Monday it has entered into a collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea, in Israel and Europe, excluding Italy. Financial terms were not disclosed. Klinge has licensed the exclusive global commercialization rights...
Illumina Starts Pilot Program With Partners to Generate Proteomics Data
Illumina Starts Pilot Program With Partners to Generate Proteomics Data
Jan 13, 2025
04:39 AM EST, 01/13/2025 (MT Newswires) -- Illumina ( ILMN ) said Monday it started a pilot proteomics program to analyze 50,000 UK Biobank samples in partnership with deCODE Genetics, Standard BioTools, Tecan, GSK (GSK), Johnson & Johnson ( JNJ ) , and Novartis ( NVS ) . Under the collaboration, deCODE Genetics will process the samples from the UK...
Copyright 2023-2026 - www.financetom.com All Rights Reserved